APO Research
Talk to an analyst

APO RESEARCH · REPORT

Biologics and Biosimilars

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

26 December 2025194 pages

Choose your research edition.

Industry ResearchBiologics and Biosimilars Industry Research Report 2026144 pages · $2,950 USDIndustry Growth & TrendsGlobal Biologics and Biosimilars Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Biologics and Biosimilars Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Biologics and Biosimilars Market Outlook and Growth Opportunities 2026207 pages · $4,250 USDMarket Analysis & ForecastGlobal Biologics and Biosimilars Market Analysis and Forecast 2026-2032203 pages · $4,950 USD

Market perspective

The global Biologics and Biosimilars market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Biologics and Biosimilars is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Biologics and Biosimilars include Sanofi, Johnson & Johnson, Novartis, Merck, Roche, Pfizer, AbbVie, United Laboratory and Tonghua Dongbao, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global Biologics and Biosimilars market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Biologics and Biosimilars and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Biologics and Biosimilars revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the Biologics and Biosimilars market size, projected growth trends, production technologies, key applications, and end-use industries.

Biologics and Biosimilars Segment by Company

Sanofi

Johnson & Johnson

Novartis

Merck

Roche

Pfizer

AbbVie

United Laboratory

Tonghua Dongbao

Sobi

Novo Nordisk

Kanghong Pharma

Innovent Biologics

Gan&Lee

Eli Lilly

Changchun High Tech

Celltrion

Biogen

Amgen

3SBIO

Biologics and Biosimilars Segment by Type

Monoclonal Antibodies

Interferon

Insulin

Vaccines

Others

Biologics and Biosimilars Segment by Application

Hospital

Retail Pharmacy

Other

Biologics and Biosimilars Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Biologics and Biosimilars market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Biologics and Biosimilars and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Biologics and Biosimilars.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of Biologics and Biosimilars in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Biologics and Biosimilars industry.

Chapter 3: Detailed analysis of Biologics and Biosimilars companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Biologics and Biosimilarsrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Biologics and Biosimilars Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Monoclonal Antibodies Table 3. Key Players of Interferon Table 4. Key Players of Insulin Table 3. Key Players of Vaccines Table 4. Key Players of Others Table 5. Global Biologics and Biosimilars Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Hospital Table 7. Key Players of Retail Pharmacy Table 8. Key Players of Other Table 9. Global Biologics and Biosimilars Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 10. Global Biologics and Biosimilars Market Size by Region (2021-2026) & (US$ Million) Table 11. Global Biologics and Biosimilars Market Share by Region (2021-2026) Table 12. Global Biologics and Biosimilars Market Size by Region (2027-2032) & (US$ Million) Table 13. Global Biologics and Biosimilars Market Share by Region (2027-2032) Table 14. Biologics and Biosimilars Industry Trends Table 15. Biologics and Biosimilars Industry Drivers Table 16. Biologics and Biosimilars Industry Opportunities and Challenges Table 17. Biologics and Biosimilars Industry Restraints Table 18. Global Biologics and Biosimilars Revenue by Company (US$ Million) & (2021-2026) Table 19. Global Biologics and Biosimilars Revenue Market Share by Company (2021-2026) Table 20. Global Biologics and Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 21. Global Biologics and Biosimilars Key Company Head Office and Area Served Table 22. Global Biologics and Biosimilars Company, Product Type & Application Table 23. Global Biologics and Biosimilars Company Establishment Date Table 24. Global Company Market Concentration Ratio (CR5 and HHI) Table 25. Global Biologics and Biosimilars by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 26. Global Biologics and Biosimilars Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 28. Global Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 29. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2026) Table 30. Global Biologics and Biosimilars Revenue Market Share by Type (2027-2032) Table 31. Global Biologics and Biosimilars Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 33. Global Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 34. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2026) Table 35. Global Biologics and Biosimilars Revenue Market Share by Application (2027-2032) Table 36. Sanofi Company Information Table 37. Sanofi Business Overview Table 38. Sanofi Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 39. Sanofi Biologics and Biosimilars Product Portfolio Table 40. Sanofi Recent Development Table 41. Johnson & Johnson Company Information Table 42. Johnson & Johnson Business Overview Table 43. Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 44. Johnson & Johnson Biologics and Biosimilars Product Portfolio Table 45. Johnson & Johnson Recent Development Table 46. Novartis Company Information Table 47. Novartis Business Overview Table 48. Novartis Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 49. Novartis Biologics and Biosimilars Product Portfolio Table 50. Novartis Recent Development Table 51. Merck Company Information Table 52. Merck Business Overview Table 53. Merck Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 54. Merck Biologics and Biosimilars Product Portfolio Table 55. Merck Recent Development Table 56. Roche Company Information Table 57. Roche Business Overview Table 58. Roche Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 59. Roche Biologics and Biosimilars Product Portfolio Table 60. Roche Recent Development Table 61. Pfizer Company Information Table 62. Pfizer Business Overview Table 63. Pfizer Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 64. Pfizer Biologics and Biosimilars Product Portfolio Table 65. Pfizer Recent Development Table 66. AbbVie Company Information Table 67. AbbVie Business Overview Table 68. AbbVie Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 69. AbbVie Biologics and Biosimilars Product Portfolio Table 70. AbbVie Recent Development Table 71. United Laboratory Company Information Table 72. United Laboratory Business Overview Table 73. United Laboratory Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 74. United Laboratory Biologics and Biosimilars Product Portfolio Table 75. United Laboratory Recent Development Table 76. Tonghua Dongbao Company Information Table 77. Tonghua Dongbao Business Overview Table 78. Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 79. Tonghua Dongbao Biologics and Biosimilars Product Portfolio Table 80. Tonghua Dongbao Recent Development Table 81. Sobi Company Information Table 82. Sobi Business Overview Table 83. Sobi Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 84. Sobi Biologics and Biosimilars Product Portfolio Table 85. Sobi Recent Development Table 86. Novo Nordisk Company Information Table 87. Novo Nordisk Business Overview Table 88. Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 89. Novo Nordisk Biologics and Biosimilars Product Portfolio Table 90. Novo Nordisk Recent Development Table 91. Kanghong Pharma Company Information Table 92. Kanghong Pharma Business Overview Table 93. Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 94. Kanghong Pharma Biologics and Biosimilars Product Portfolio Table 95. Kanghong Pharma Recent Development Table 96. Innovent Biologics Company Information Table 97. Innovent Biologics Business Overview Table 98. Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 99. Innovent Biologics Biologics and Biosimilars Product Portfolio Table 100. Innovent Biologics Recent Development Table 101. Gan&Lee Company Information Table 102. Gan&Lee Business Overview Table 103. Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 104. Gan&Lee Biologics and Biosimilars Product Portfolio Table 105. Gan&Lee Recent Development Table 106. Eli Lilly Company Information Table 107. Eli Lilly Business Overview Table 108. Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 109. Eli Lilly Biologics and Biosimilars Product Portfolio Table 110. Eli Lilly Recent Development Table 111. Changchun High Tech Company Information Table 112. Changchun High Tech Business Overview Table 113. Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 114. Changchun High Tech Biologics and Biosimilars Product Portfolio Table 115. Changchun High Tech Recent Development Table 116. Celltrion Company Information Table 117. Celltrion Business Overview Table 118. Celltrion Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 119. Celltrion Biologics and Biosimilars Product Portfolio Table 120. Celltrion Recent Development Table 121. Biogen Company Information Table 122. Biogen Business Overview Table 123. Biogen Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 124. Biogen Biologics and Biosimilars Product Portfolio Table 125. Biogen Recent Development Table 126. Amgen Company Information Table 127. Amgen Business Overview Table 128. Amgen Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 129. Amgen Biologics and Biosimilars Product Portfolio Table 130. Amgen Recent Development Table 131. 3SBIO Company Information Table 132. 3SBIO Business Overview Table 133. 3SBIO Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026) Table 134. 3SBIO Biologics and Biosimilars Product Portfolio Table 135. 3SBIO Recent Development Table 136. North America Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 137. North America Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 138. North America Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 139. North America Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 140. North America Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 141. North America Biologics and Biosimilars Market Size by Country (2021-2026) Table 142. North America Biologics and Biosimilars Market Size by Country (2027-2032) Table 143. Europe Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 144. Europe Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 145. Europe Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 146. Europe Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 147. Europe Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 148. Europe Biologics and Biosimilars Market Size by Country (2021-2026) Table 149. Europe Biologics and Biosimilars Market Size by Country (2027-2032) Table 150. China Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 151. China Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 152. China Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 153. China Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 154. Asia Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 155. Asia Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 156. Asia Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 157. Asia Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 158. Asia Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 159. Asia Biologics and Biosimilars Market Size by Country (2021-2026) Table 160. Asia Biologics and Biosimilars Market Size by Country (2027-2032) Table 161. South America, Middle East & Africa Biologics and Biosimilars Market Size by Type (2021-2026) & (US$ Million) Table 162. South America, Middle East & Africa Biologics and Biosimilars Market Size by Type (2027-2032) & (US$ Million) Table 163. South America, Middle East & Africa Biologics and Biosimilars Market Size by Application (2021-2026) & (US$ Million) Table 164. South America, Middle East & Africa Biologics and Biosimilars Market Size by Application (2027-2032) & (US$ Million) Table 165. South America, Middle East & Africa Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 166. South America, Middle East & Africa Biologics and Biosimilars Market Size by Country (2021-2026) Table 167. South America, Middle East & Africa Biologics and Biosimilars Market Size by Country (2027-2032) Table 168. Research Programs/Design for This Report Table 169. Authors List of This Report Table 170. Secondary Sources Table 171. Primary Sources List of Figures Figure 1. Biologics and Biosimilars Product Image Figure 2. Global Biologics and Biosimilars Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global Biologics and Biosimilars Market Share by Type: 2025 VS 2032 Figure 4. Monoclonal Antibodies Image Figure 5. Interferon Image Figure 6. Insulin Image Figure 7. Vaccines Image Figure 8. Others Image Figure 9. Global Biologics and Biosimilars Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global Biologics and Biosimilars Market Share by Application: 2025 VS 2032 Figure 11. Hospital Image Figure 12. Retail Pharmacy Image Figure 13. Other Image Figure 14. Global Biologics and Biosimilars Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 15. Global Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 16. Global Biologics and Biosimilars Market Share by Region: 2025 VS 2032 Figure 17. Years Considered Figure 18. Global Biologics and Biosimilars Market Share by Players in 2025 Figure 19. Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025 Figure 20. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 21. Global Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 22. Global Biologics and Biosimilars Revenue Market Share by Type (2021-2032) Figure 23. Global Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Biologics and Biosimilars Revenue Market Share by Application (2021-2032) Figure 25. North America Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 26. North America Biologics and Biosimilars Market Share by Type (2021-2032) Figure 27. North America Biologics and Biosimilars Market Share by Application (2021-2032) Figure 28. North America Biologics and Biosimilars Market Share by Country (2021-2032) Figure 29. United States Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 30. Canada Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 31. Mexico Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 32. Europe Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 33. Europe Biologics and Biosimilars Market Share by Type (2021-2032) Figure 34. Europe Biologics and Biosimilars Market Share by Application (2021-2032) Figure 35. Europe Biologics and Biosimilars Market Share by Country (2021-2032) Figure 36. Germany Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 37. France Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 38. U.K. Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 39. Italy Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 40. Russia Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 41. Nordic Countries Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 42. China Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 43. China Biologics and Biosimilars Market Share by Type (2021-2032) Figure 44. China Biologics and Biosimilars Market Share by Application (2021-2032) Figure 45. Asia Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 46. Asia Biologics and Biosimilars Market Share by Type (2021-2032) Figure 47. Asia Biologics and Biosimilars Market Share by Application (2021-2032) Figure 48. Asia Biologics and Biosimilars Market Share by Country (2021-2032) Figure 49. Japan Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 50. South Korea Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 51. Taiwan Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 52. Southeast Asia Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 53. India Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 54. Australia Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 55. South America, Middle East & Africa Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa Biologics and Biosimilars Market Share by Type (2021-2032) Figure 57. South America, Middle East & Africa Biologics and Biosimilars Market Share by Application (2021-2032) Figure 58. South America, Middle East & Africa Biologics and Biosimilars Market Share by Country (2021-2032) Figure 59. Brazil Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 60. South Africa Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 61. Saudi Arabia Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 62. Turkey Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 63. Argentina Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 64. UAE Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 65. Egypt Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 66. Chile Biologics and Biosimilars Market Size (2021-2032) & (US$ Million) Figure 67. Research Process Figure 68. Key Executives Interviewed

Scope & coverage.

Types
  • Monoclonal Antibodies
  • Interferon
  • Insulin
  • Vaccines
  • Others
Applications
  • Hospital
  • Retail Pharmacy
  • Other
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Novartis
  • Merck
  • Roche
  • Pfizer
  • AbbVie
  • United Laboratory
  • Tonghua Dongbao
  • Sobi
  • Novo Nordisk
  • Kanghong Pharma
  • Innovent Biologics
  • Gan&Lee
  • Eli Lilly
  • Changchun High Tech
  • Celltrion
  • Biogen
  • Amgen
  • 3SBIO

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global Biologics and Biosimilars Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Monoclonal Antibodies
  5. 1.2.3 Interferon
  6. 1.2.4 Insulin
  7. 1.2.5 Vaccines
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global Biologics and Biosimilars Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Hospital
  12. 1.3.3 Retail Pharmacy
  13. 1.3.4 Other
  14. 1.4 Global Market Growth Prospects
  15. 1.5 Global Biologics and Biosimilars Growth Trends by Region
  16. 1.5.1 Global Biologics and Biosimilars Market Size by Region: 2021 VS 2025 VS 2032
  17. 1.5.2 Biologics and Biosimilars Market Size by Region (2021-2026)
  18. 1.5.3 Biologics and Biosimilars Market Size by Region (2027-2032)
  19. 1.6 Assumptions and Limitations
  20. 1.7 Study Goals and Objectives
  21. 1.8 Years Considered
2 Global Biologics and Biosimilars Market Dynamics
  1. 2.1 Biologics and Biosimilars Industry Trends
  2. 2.2 Biologics and Biosimilars Industry Drivers
  3. 2.3 Biologics and Biosimilars Industry Opportunities and Challenges
  4. 2.4 Biologics and Biosimilars Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global Biologics and Biosimilars Revenue by Company (2021-2026)
  2. 3.2 Global Biologics and Biosimilars Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global Biologics and Biosimilars Key Company Head office and Area Served
  4. 3.4 Global Biologics and Biosimilars Company, Product Type & Application
  5. 3.5 Global Biologics and Biosimilars Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global Biologics and Biosimilars Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 Biologics and Biosimilars Players Market Share by Revenue in 2025
  9. 3.6.3 2025 Biologics and Biosimilars Tier 1, Tier 2, and Tier 3
4 Biologics and Biosimilars Market by Type
  1. 4.1 Global Biologics and Biosimilars Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global Biologics and Biosimilars Market Size by Type (2021-2032)
  3. 4.3 Global Biologics and Biosimilars Market Size Share by Type (2021-2032)
5 Biologics and Biosimilars Market by Application
  1. 5.1 Global Biologics and Biosimilars Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global Biologics and Biosimilars Market Size by Application (2021-2032)
  3. 5.3 Global Biologics and Biosimilars Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 Sanofi
  2. 6.1.1 Sanofi Company Information
  3. 6.1.2 Sanofi Business Overview
  4. 6.1.3 Sanofi Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 Sanofi Biologics and Biosimilars Product Portfolio
  6. 6.1.5 Sanofi Recent Developments
  7. 6.2 Johnson & Johnson
  8. 6.2.1 Johnson & Johnson Company Information
  9. 6.2.2 Johnson & Johnson Business Overview
  10. 6.2.3 Johnson & Johnson Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Johnson & Johnson Biologics and Biosimilars Product Portfolio
  12. 6.2.5 Johnson & Johnson Recent Developments
  13. 6.3 Novartis
  14. 6.3.1 Novartis Company Information
  15. 6.3.2 Novartis Business Overview
  16. 6.3.3 Novartis Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Novartis Biologics and Biosimilars Product Portfolio
  18. 6.3.5 Novartis Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Merck Biologics and Biosimilars Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Roche
  26. 6.5.1 Roche Company Information
  27. 6.5.2 Roche Business Overview
  28. 6.5.3 Roche Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Roche Biologics and Biosimilars Product Portfolio
  30. 6.5.5 Roche Recent Developments
  31. 6.6 Pfizer
  32. 6.6.1 Pfizer Company Information
  33. 6.6.2 Pfizer Business Overview
  34. 6.6.3 Pfizer Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Pfizer Biologics and Biosimilars Product Portfolio
  36. 6.6.5 Pfizer Recent Developments
  37. 6.7 AbbVie
  38. 6.7.1 AbbVie Company Information
  39. 6.7.2 AbbVie Business Overview
  40. 6.7.3 AbbVie Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 AbbVie Biologics and Biosimilars Product Portfolio
  42. 6.7.5 AbbVie Recent Developments
  43. 6.8 United Laboratory
  44. 6.8.1 United Laboratory Company Information
  45. 6.8.2 United Laboratory Business Overview
  46. 6.8.3 United Laboratory Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 United Laboratory Biologics and Biosimilars Product Portfolio
  48. 6.8.5 United Laboratory Recent Developments
  49. 6.9 Tonghua Dongbao
  50. 6.9.1 Tonghua Dongbao Company Information
  51. 6.9.2 Tonghua Dongbao Business Overview
  52. 6.9.3 Tonghua Dongbao Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Tonghua Dongbao Biologics and Biosimilars Product Portfolio
  54. 6.9.5 Tonghua Dongbao Recent Developments
  55. 6.10 Sobi
  56. 6.10.1 Sobi Company Information
  57. 6.10.2 Sobi Business Overview
  58. 6.10.3 Sobi Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Sobi Biologics and Biosimilars Product Portfolio
  60. 6.10.5 Sobi Recent Developments
  61. 6.11 Novo Nordisk
  62. 6.11.1 Novo Nordisk Company Information
  63. 6.11.2 Novo Nordisk Business Overview
  64. 6.11.3 Novo Nordisk Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Novo Nordisk Biologics and Biosimilars Product Portfolio
  66. 6.11.5 Novo Nordisk Recent Developments
  67. 6.12 Kanghong Pharma
  68. 6.12.1 Kanghong Pharma Company Information
  69. 6.12.2 Kanghong Pharma Business Overview
  70. 6.12.3 Kanghong Pharma Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Kanghong Pharma Biologics and Biosimilars Product Portfolio
  72. 6.12.5 Kanghong Pharma Recent Developments
  73. 6.13 Innovent Biologics
  74. 6.13.1 Innovent Biologics Company Information
  75. 6.13.2 Innovent Biologics Business Overview
  76. 6.13.3 Innovent Biologics Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Innovent Biologics Biologics and Biosimilars Product Portfolio
  78. 6.13.5 Innovent Biologics Recent Developments
  79. 6.14 Gan&Lee
  80. 6.14.1 Gan&Lee Company Information
  81. 6.14.2 Gan&Lee Business Overview
  82. 6.14.3 Gan&Lee Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Gan&Lee Biologics and Biosimilars Product Portfolio
  84. 6.14.5 Gan&Lee Recent Developments
  85. 6.15 Eli Lilly
  86. 6.15.1 Eli Lilly Company Information
  87. 6.15.2 Eli Lilly Business Overview
  88. 6.15.3 Eli Lilly Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Eli Lilly Biologics and Biosimilars Product Portfolio
  90. 6.15.5 Eli Lilly Recent Developments
  91. 6.16 Changchun High Tech
  92. 6.16.1 Changchun High Tech Company Information
  93. 6.16.2 Changchun High Tech Business Overview
  94. 6.16.3 Changchun High Tech Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Changchun High Tech Biologics and Biosimilars Product Portfolio
  96. 6.16.5 Changchun High Tech Recent Developments
  97. 6.17 Celltrion
  98. 6.17.1 Celltrion Company Information
  99. 6.17.2 Celltrion Business Overview
  100. 6.17.3 Celltrion Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Celltrion Biologics and Biosimilars Product Portfolio
  102. 6.17.5 Celltrion Recent Developments
  103. 6.18 Biogen
  104. 6.18.1 Biogen Company Information
  105. 6.18.2 Biogen Business Overview
  106. 6.18.3 Biogen Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Biogen Biologics and Biosimilars Product Portfolio
  108. 6.18.5 Biogen Recent Developments
  109. 6.19 Amgen
  110. 6.19.1 Amgen Company Information
  111. 6.19.2 Amgen Business Overview
  112. 6.19.3 Amgen Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 Amgen Biologics and Biosimilars Product Portfolio
  114. 6.19.5 Amgen Recent Developments
  115. 6.20 3SBIO
  116. 6.20.1 3SBIO Company Information
  117. 6.20.2 3SBIO Business Overview
  118. 6.20.3 3SBIO Biologics and Biosimilars Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 3SBIO Biologics and Biosimilars Product Portfolio
  120. 6.20.5 3SBIO Recent Developments
7 North America
  1. 7.1 North America Biologics and Biosimilars Market Size (2021-2032)
  2. 7.2 North America Biologics and Biosimilars Market Size by Type
  3. 7.2.1 North America Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 7.2.2 North America Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 7.2.3 North America Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 7.3 North America Biologics and Biosimilars Market Size by Application
  7. 7.3.1 North America Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 7.3.2 North America Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 7.3.3 North America Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 7.4 North America Biologics and Biosimilars Market Size by Country
  11. 7.4.1 North America Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 7.4.3 North America Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 7.4.4 North America Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe Biologics and Biosimilars Market Size (2021-2032)
  2. 8.2 Europe Biologics and Biosimilars Market Size by Type
  3. 8.2.1 Europe Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 8.2.2 Europe Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 8.2.3 Europe Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 8.3 Europe Biologics and Biosimilars Market Size by Application
  7. 8.3.1 Europe Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 8.3.2 Europe Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 8.3.3 Europe Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 8.4 Europe Biologics and Biosimilars Market Size by Country
  11. 8.4.1 Europe Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 8.4.3 Europe Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 8.4.4 Europe Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China Biologics and Biosimilars Market Size (2021-2032)
  2. 9.2 China Biologics and Biosimilars Market Size by Type
  3. 9.2.1 China Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 9.2.2 China Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 9.2.3 China Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 9.3 China Biologics and Biosimilars Market Size by Application
  7. 9.3.1 China Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 9.3.2 China Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 9.3.3 China Biologics and Biosimilars Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia Biologics and Biosimilars Market Size (2021-2032)
  2. 10.2 Asia Biologics and Biosimilars Market Size by Type
  3. 10.2.1 Asia Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 10.2.2 Asia Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 10.2.3 Asia Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 10.3 Asia Biologics and Biosimilars Market Size by Application
  7. 10.3.1 Asia Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 10.3.2 Asia Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 10.3.3 Asia Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 10.4 Asia Biologics and Biosimilars Market Size by Country
  11. 10.4.1 Asia Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 10.4.3 Asia Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 10.4.4 Asia Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa Biologics and Biosimilars Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa Biologics and Biosimilars Market Size by Type
  3. 11.2.1 South America, Middle East & Africa Biologics and Biosimilars Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa Biologics and Biosimilars Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa Biologics and Biosimilars Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa Biologics and Biosimilars Market Size by Application
  7. 11.3.1 South America, Middle East & Africa Biologics and Biosimilars Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa Biologics and Biosimilars Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa Biologics and Biosimilars Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa Biologics and Biosimilars Market Size by Country
  11. 11.4.1 South America, Middle East & Africa Biologics and Biosimilars Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa Biologics and Biosimilars Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa Biologics and Biosimilars Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa Biologics and Biosimilars Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst